364 related articles for article (PubMed ID: 25655233)
1. Comprehensive mutation profiling by next-generation sequencing of effusion fluids from patients with high-grade serous ovarian carcinoma.
Shah RH; Scott SN; Brannon AR; Levine DA; Lin O; Berger MF
Cancer Cytopathol; 2015 May; 123(5):289-97. PubMed ID: 25655233
[TBL] [Abstract][Full Text] [Related]
2. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
3. Intraindividual genomic heterogeneity of high-grade serous carcinoma of the ovary and clinical utility of ascitic cancer cells for mutation profiling.
Choi YJ; Rhee JK; Hur SY; Kim MS; Lee SH; Chung YJ; Kim TM; Lee SH
J Pathol; 2017 Jan; 241(1):57-66. PubMed ID: 27741368
[TBL] [Abstract][Full Text] [Related]
4. Targeted deep sequencing of effusion cytology samples is feasible, informs spatiotemporal tumor evolution, and has clinical and diagnostic utility.
Leichsenring J; Volckmar AL; Kirchner M; Kazdal D; Kriegsmann M; Stögbauer F; Bockmayr T; Klauschen F; Herth FJF; Penzel R; Warth A; Schirmacher P; Endris V; Stenzinger A
Genes Chromosomes Cancer; 2018 Feb; 57(2):70-79. PubMed ID: 29044880
[TBL] [Abstract][Full Text] [Related]
5. Targeted Genomic Sequencing Reveals Novel
Jung YY; Woo HY; Kim HS
Anticancer Res; 2019 Jun; 39(6):2883-2889. PubMed ID: 31177126
[TBL] [Abstract][Full Text] [Related]
6. Profiling cancer gene mutations in longitudinal epithelial ovarian cancer biopsies by targeted next-generation sequencing: a retrospective study.
Beltrame L; Di Marino M; Fruscio R; Calura E; Chapman B; Clivio L; Sina F; Mele C; Iatropoulos P; Grassi T; Fotia V; Romualdi C; Martini P; Noris M; Paracchini L; Craparotta I; Petrillo M; Milani R; Perego P; Ravaggi A; Zambelli A; Ronchetti E; D'Incalci M; Marchini S
Ann Oncol; 2015 Jul; 26(7):1363-71. PubMed ID: 25846551
[TBL] [Abstract][Full Text] [Related]
7. An Integrative Genomic Analysis of Formalin Fixed Paraffin-Embedded Archived Serous Ovarian Carcinoma Comparing Long-term and Short-term Survivors.
Stålberg K; Crona J; Razmara M; Taslica D; Skogseid B; Stålberg P
Int J Gynecol Cancer; 2016 Jul; 26(6):1027-32. PubMed ID: 27177282
[TBL] [Abstract][Full Text] [Related]
8. Assessment of TP53 mutation using purified tissue samples of ovarian serous carcinomas reveals a higher mutation rate than previously reported and does not correlate with drug resistance.
Salani R; Kurman RJ; Giuntoli R; Gardner G; Bristow R; Wang TL; Shih IM
Int J Gynecol Cancer; 2008; 18(3):487-91. PubMed ID: 17692090
[TBL] [Abstract][Full Text] [Related]
9. New Challenges in Tumor Mutation Heterogeneity in Advanced Ovarian Cancer by a Targeted Next-Generation Sequencing (NGS) Approach.
Garziera M; Roncato R; Montico M; De Mattia E; Gagno S; Poletto E; Scalone S; Canzonieri V; Giorda G; Sorio R; Cecchin E; Toffoli G
Cells; 2019 Jun; 8(6):. PubMed ID: 31197119
[TBL] [Abstract][Full Text] [Related]
10. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive genomic profiling of high-grade serous ovarian carcinoma from Chinese patients identifies co-occurring mutations in the Ras/Raf pathway with TP53.
Zhong F; Zhu T; Pan X; Zhang Y; Yang H; Wang X; Hu J; Han H; Mei L; Chen D; Wang K; Zhou X; Li X; Dong X
Cancer Med; 2019 Jul; 8(8):3928-3935. PubMed ID: 31124283
[TBL] [Abstract][Full Text] [Related]
12. Molecular characterization of serous ovarian carcinoma using a multigene next generation sequencing cancer panel approach.
Ab Mutalib NS; Syafruddin SE; Md Zain RR; Mohd Dali AZ; Mohd Yunos RI; Saidin S; Jamal R; Mokhtar NM
BMC Res Notes; 2014 Nov; 7():805. PubMed ID: 25404506
[TBL] [Abstract][Full Text] [Related]
13. Recurrent BRCA1 Mutation, but no BRCA2 Mutation, in Vietnamese Patients with Ovarian Carcinoma Detected with Next Generation Sequencing.
Vu HA; Phu ND; Khuong LT; Hoa PH; Nhu BTH; Nhan VT; Thanh LQ; Sinh ND; Chi HT; Quan ND; Binh NT
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2331-2335. PubMed ID: 32856862
[TBL] [Abstract][Full Text] [Related]
14. Expression of BRAF V600E mutant protein in epithelial ovarian tumors.
Preusser M; Capper D; Berghoff AS; Horvat R; Wrba F; Schindl M; Schoppmann SF; von Deimling A; Birner P
Appl Immunohistochem Mol Morphol; 2013 Mar; 21(2):159-64. PubMed ID: 22820660
[TBL] [Abstract][Full Text] [Related]
15. Comprehensive genomic profiling reveals ubiquitous KRAS mutations and frequent PIK3CA mutations in ovarian seromucinous borderline tumor.
Wu RC; Chen SJ; Chen HC; Tan KT; Jung SM; Lin CY; Chao AS; Huang KG; Chou HH; Chang TC; Chao A; Lai CH
Mod Pathol; 2020 Dec; 33(12):2534-2543. PubMed ID: 32616873
[TBL] [Abstract][Full Text] [Related]
16. Intratumoral heterogeneity in a minority of ovarian low-grade serous carcinomas.
Tone AA; McConechy MK; Yang W; Ding J; Yip S; Kong E; Wong KK; Gershenson DM; Mackay H; Shah S; Gilks B; Tinker AV; Clarke B; McAlpine JN; Huntsman D
BMC Cancer; 2014 Dec; 14():982. PubMed ID: 25523272
[TBL] [Abstract][Full Text] [Related]
17. Distinct evolutionary trajectories of primary high-grade serous ovarian cancers revealed through spatial mutational profiling.
Bashashati A; Ha G; Tone A; Ding J; Prentice LM; Roth A; Rosner J; Shumansky K; Kalloger S; Senz J; Yang W; McConechy M; Melnyk N; Anglesio M; Luk MT; Tse K; Zeng T; Moore R; Zhao Y; Marra MA; Gilks B; Yip S; Huntsman DG; McAlpine JN; Shah SP
J Pathol; 2013 Sep; 231(1):21-34. PubMed ID: 23780408
[TBL] [Abstract][Full Text] [Related]
18. Comprehensive genomic sequencing of paired ovarian cancers reveals discordance in genes that determine clinical trial eligibility.
Fehniger JE; Berger AA; Juckett L; Elvin J; Levine DA; Zajchowski DA
Gynecol Oncol; 2019 Dec; 155(3):473-482. PubMed ID: 31703812
[TBL] [Abstract][Full Text] [Related]
19. BRCA somatic and germline mutation detection in paraffin embedded ovarian cancers by next-generation sequencing.
Mafficini A; Simbolo M; Parisi A; Rusev B; Luchini C; Cataldo I; Piazzola E; Sperandio N; Turri G; Franchi M; Tortora G; Bovo C; Lawlor RT; Scarpa A
Oncotarget; 2016 Jan; 7(2):1076-83. PubMed ID: 26745875
[TBL] [Abstract][Full Text] [Related]
20. Applying Precision Medicine to Ovarian Cancer: Proof-of-Principle for a "Molecular Second Look".
Schwartz M; Camacho-Vanegas O; Wood AM; Dashkoff M; Whitelock C; Harkins TT; Cohen CJ; Beddoe AM; Dottino P; Martignetti JA
Int J Gynecol Cancer; 2018 Mar; 28(3):479-485. PubMed ID: 29324546
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
